Virbac Posts H1 2026 Revenue of €768 Million, Up 7.4%, as Companion Animal Sales Grow 10%
Executive Summary. French animal health group Virbac reported first-half 2026 revenue of €768 million, up 7.4% at constant exchange rates and scope, with companion animal sales rising 10.0% and farm animal sales 6.7%, Reuters reported on 17 September 2026. Recurring operating profit excluding acquisition-related amortisation rose 6.8% to €144.2 million, and management confirmed full-year guidance at the top of its 5.5%-7.5% range.
Key Facts
- Company
- Virbac (listed animal health group, headquartered in France)
- Country
- France — global operations
- Industry
- Animal health / veterinary pharmaceuticals
- Category
- Half-year results, companion animal and farm animal segments
- Event
- H1 2026 results and confirmation of 2026 outlook
- Date
- 2026-09-17
- Location
- Reported from Gdansk; company based in Carros, France
- Source
- Reuters
What Happened
Virbac’s first-half revenue came in at €768 million, up 7.4% on a constant-exchange-rate and constant-scope basis. Companion animals — dogs, cats and the practices that treat them — grew 10.0%, ahead of the farm animal business at 6.7%. Recurring operating profit, stripping out amortisation of assets arising from acquisitions, rose 6.8% to €144.2 million from €135.0 million. The company kept its 2026 guidance, pointing to the upper end of a 5.5%-7.5% growth band.
CEO Paul Martingell attributed the result to what the group calls its Supercharge platforms, which grew roughly 12% in the period once Thyronorm is stripped out. The feline hyperthyroidism treatment, bought from Norbrook in December 2025 and sold as Felanorm in the United States, added a further 3.7 percentage points to platform growth.
Background
Virbac sits in a part of animal health that behaves differently from branded pet food. Revenue is prescribed rather than shopped for, the customer is a veterinarian rather than a consumer, and growth is driven by clinical need and practice economics rather than by shelf placement. That makes it a useful proxy for what is actually happening inside veterinary medicine — arguably more useful than retail scanner data, which only captures what owners buy without a prescription.
The company has spent the last few years adding specialty assets rather than chasing scale: Thyronorm for feline hyperthyroidism, plus the Porus-One and Vetcare deals flagged alongside these results. The pattern is deliberate — high-margin, clinically differentiated products that a practice recommends by name.
Industry Context
A 10% companion animal print, in a year when pet food volumes have been soft in several markets, says something specific: spending on medical and preventive care is holding up better than spending on bowls. Parasiticides, vaccines, dermatology and dental products are non-discretionary in a way that premium food is not. Owners trading down in the grocery aisle are still authorising flea, tick and worm protection and dental care at the practice.
It also matters where the money lands. Most companion animal revenue reaches the owner through a vet clinic or an animal hospital near me search, not through a retail shelf. That makes distributors and group purchasing organisations the real gatekeepers, and it means manufacturer growth translates into clinic inventory decisions rather than into promotional calendars.
Market & Business Impact
For suppliers, the read-through is about mix and margin. Specialty and therapeutic lines — endocrinology, dermatology, dentistry — carry better economics than commodity parasiticide volume, and Virbac’s willingness to pay for them (Thyronorm, Porus-One, Vetcare) signals where the industry thinks defensible margin lives. Pet dental care is the clearest example: it is a category that only converts when a professional raises it, which is why it grows with practice throughput rather than with retail traffic.
The confirmation of guidance at the top of the range is a second signal. Animal health companies do not usually raise the floor of a guidance range midway through a year unless the underlying demand is broad, not just a single product launch. Reuters reported the outlook was confirmed with the CEO citing platform scaling and the successful Thyronorm integration.
Companies & Brands Involved
Virbac is the reporting company; Paul Martingell is CEO. Norbrook is the seller of Thyronorm, now marketed by Virbac as Felanorm in the United States. Competitors in companion animal health — the global parasiticide and vaccine majors — compete for the same practice shelf, though none was named in the report. Virbac’s own distribution runs through veterinary wholesalers and direct practice sales rather than through pet retail chains, which is precisely why its numbers are worth watching as a proxy for clinic-level demand. GPI tracks the manufacturers and distributors in this segment in the company index.
Data & Evidence
All figures are from Reuters’ 17 September 2026 report on Virbac’s half-year results: revenue €768 million (+7.4% at constant exchange rates and scope); companion animal growth 10.0%; farm animal growth 6.7%; recurring operating profit excluding acquisition-related amortisation €144.2 million, +6.8% from €135.0 million; 2026 outlook confirmed at the upper end of 5.5%-7.5%; Supercharge platforms up about 12% excluding Thyronorm, with Thyronorm adding 3.7 percentage points; Thyronorm acquired from Norbrook in December 2025 and sold as Felanorm in the US; Porus-One and Vetcare highlighted as specialty-asset deals. Reuters reported at an exchange rate of $1 = €0.8713.
What This Means for the Pet Industry
GPI’s read: Virbac’s half-year is the cleanest available evidence that pet health spend is decoupling from pet product spend. Ten percent companion animal growth against soft food volumes in several markets tells you owners are protecting medical care and trimming discretionary categories — a pattern that will keep favouring anything dispensed or recommended in a clinic over anything bought on a shelf.
The second implication is about consolidation. Virbac is buying small specialty assets and folding them into platforms, and the 3.7-point contribution from a single December acquisition shows how fast that can move the needle. Expect more of the same across animal health: the large parasiticide franchises are mature, so growth is being bought in therapeutic niches. One caveat — the profit figure cited excludes amortisation of acquisition-related assets, so the reported 6.8% improvement flatters the economics of an acquisition-led strategy; investors should look at the reported operating profit line before drawing conclusions about underlying margin.
Key Takeaways
- Virbac’s H1 2026 revenue reached €768 million, up 7.4% at constant exchange rates and scope.
- Companion animal sales grew 10.0%, outpacing farm animal growth of 6.7%.
- Recurring operating profit excluding acquisition-related amortisation rose 6.8% to €144.2 million.
- 2026 guidance was confirmed at the upper end of the 5.5%-7.5% target range.
- The Thyronorm acquisition contributed 3.7 percentage points to platform growth and strengthened Virbac’s endocrinology business.
Frequently Asked Questions
How did Virbac perform in the first half of 2026?
Revenue of €768 million, up 7.4% at constant exchange rates and scope, with recurring operating profit excluding acquisition-related amortisation up 6.8% to €144.2 million.
Which segment grew faster?
Companion animals, up 10.0%, against farm animal growth of 6.7% — a gap that reflects sustained spending on pet medical and preventive care.
What are Virbac’s Supercharge platforms?
The group’s priority growth platforms, up about 12% in H1 2026 excluding Thyronorm, with the acquisition adding 3.7 percentage points. CEO Paul Martingell credited their scaling power for the profit improvement.
What did Virbac acquire recently?
Thyronorm, a feline hyperthyroidism treatment sold as Felanorm in the United States, acquired from Norbrook in December 2025, plus the Porus-One and Vetcare specialty deals.
Why does companion animal growth matter to veterinary clinics?
Because that revenue is dispensed or prescribed in practice. A 10% rise means more parasiticide, vaccine, dermatology and dental product moving through clinic inventory rather than retail shelves.
Sources
- Reuters — Virbac confirms outlook as Supercharge platforms drive profit growth, 2026-09-17
- Virbac — corporate and investor information, 2026
